Bitget and BlockSec have released a joint report introducing the UEX Security Standard, a system-level framework designed to safeguard multi-asset trading acrossBitget and BlockSec have released a joint report introducing the UEX Security Standard, a system-level framework designed to safeguard multi-asset trading across

Bitget And BlockSec Unveil UEX Security Standard, Establishing New Benchmark For Universal Exchange Security

2026/02/09 22:30
3 min read
Bitget

Bitget, the global Universal Exchange (UEX) operator, has released a new research report titled The UEX Security Standard: From Proof to Protection, produced in collaboration with blockchain security firm BlockSec. The report introduces a system-level security framework aimed at exchanges managing crypto, tokenized assets, and traditional financial instruments within unified account environments.

As trading platforms evolve into Universal Exchanges, a term first coined by Bitget CEO Gracy Chen at the company’s seventh anniversary, security considerations extend beyond single-asset custody or on-chain protections. Unified margin systems, shared settlement infrastructure, and cross-market access create new vulnerabilities, where failures at the account, data, or permission layer can propagate across multiple products and asset classes. The report shifts the focus from isolated controls to continuous, verifiable system resilience.

The UEX Security Standard outlines five key benchmarks for next-generation exchange security: verifiable solvency, multi-asset risk isolation, data security and privacy protection, AI-driven dynamic monitoring, and resilient application and infrastructure defenses. These measures are designed to contain risks, ensure correctness, and maintain trust as platform complexity increases.

The framework is informed by existing safeguards at Bitget, including regular Proof of Reserves reporting and a robust Protection Fund, augmented by collaboration with BlockSec on real-time monitoring, offensive security testing, incident response readiness, and compliance-grade controls such as AML screening and fund tracing.

Bitget And BlockSec Highlight System-Level Security Imperatives For Universal Exchanges In New Industry Report

“The transition to Universal Exchanges changes the nature of security risk,” said Gracy Chen, CEO of Bitget in a written statement. “Security can no longer focus on individual assets or reactive disclosure. It must operate at the system level, where risks are identified early, isolated by design, and verified under real-world conditions,” he added. 

BlockSec CEO Yajin Zhou added, “UEX is not just a product upgrade. It is a structural shift in how trading infrastructure and security must work. When you combine crypto-native assets with stocks, ETFs, and other off-chain instruments, the security boundary expands dramatically.” 

“Platforms must prove asset transparency, ensure pricing integrity, and secure off-chain dependencies to the same standard as on-chain systems. UEX demands a unified, verifiable security framework that can protect multi-asset trading at scale,” he said.

The report also emphasizes transparency, emergency response readiness, and user education, presenting security as a dynamic discipline that must evolve alongside product complexity and market structure. It is positioned as a reference for exchanges, regulators, and market participants navigating the next phase of multi-asset trading infrastructure.

The post Bitget And BlockSec Unveil UEX Security Standard, Establishing New Benchmark For Universal Exchange Security appeared first on Metaverse Post.

Disclaimer: The articles reposted on this site are sourced from public platforms and are provided for informational purposes only. They do not necessarily reflect the views of MEXC. All rights remain with the original authors. If you believe any content infringes on third-party rights, please contact service@support.mexc.com for removal. MEXC makes no guarantees regarding the accuracy, completeness, or timeliness of the content and is not responsible for any actions taken based on the information provided. The content does not constitute financial, legal, or other professional advice, nor should it be considered a recommendation or endorsement by MEXC.

You May Also Like

Vàng Cán Mốc Lịch Sử 5.000 USD: Khi Dự Báo Của CEO Bitget Gracy Chen Trở Thành Hiện Thực Và Tầm Nhìn Về Đích Đến 5.400 USD

Vàng Cán Mốc Lịch Sử 5.000 USD: Khi Dự Báo Của CEO Bitget Gracy Chen Trở Thành Hiện Thực Và Tầm Nhìn Về Đích Đến 5.400 USD

Thị trường tài chính toàn cầu vừa chứng kiến một khoảnh khắc lịch sử chấn động: Giá Vàng thế giới [...] The post Vàng Cán Mốc Lịch Sử 5.000 USD: Khi Dự Báo Của
Share
Vneconomics2026/02/10 16:26
Why the Bitcoin Boom Is Not Another Tulip Mania

Why the Bitcoin Boom Is Not Another Tulip Mania

Bitcoin is an amazing success story. It was only invented in January of 2009 and was only worth a tiny fraction of a cent for each token. Over just a few years
Share
Medium2026/02/10 15:44
Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution

Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution

The post Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution appeared on BitcoinEthereumNews.com. In this week’s edition of InnovationRx, we look at possible pain treatments from cannabis, risks of new vaccine restrictions, virtual clinical trials at the Mayo Clinic, GSK’s $30 billion U.S. manufacturing commitment, and more. To get it in your inbox, subscribe here. Despite their addictive nature, opioids continue to be a major treatment for pain due to a lack of effective alternatives. In an effort to boost new drugs, the FDA released new guidelines for non-opioid painkillers last week. But making these drugs hasn’t been easy. Vertex Pharmaceuticals received FDA approval for its non-opioid Journavx in January, then abandoned a next generation drug after a failed clinical trial earlier this summer. Acadia similarly abandoned a promising candidate after a failed trial in 2022. One possible basis for non-opioids might be cannabis. Earlier this year, researchers at Washington University at St. Louis and Stanford published a study showing that a cannabis-derived compound successfully eased pain in mice with minimal side effects. Munich-based pharmaceutical company Vertanical is perhaps the furthest along in this quest. It is developing a cannabinoid-based extract to treat chronic pain it hopes will soon become an approved medicine, first in the European Union and eventually in the United States. The drug, currently called Ver-01, packs enough low levels of cannabinoids (including THC) to relieve pain, but not so much that patients get high. Founder Clemens Fischer, a 50-year-old medical doctor and serial pharmaceutical and supplement entrepreneur, hopes it will become the first cannabis-based painkiller prescribed by physicians and covered by insurance. Fischer founded Vertanical, with his business partner Madlena Hohlefelder, in 2017, and has invested more than $250 million of his own money in it. With a cannabis cultivation site and drug manufacturing plant in Denmark, Vertanical has successfully passed phase III clinical trials in Germany and expects…
Share
BitcoinEthereumNews2025/09/18 05:26